We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Ask ADVFN Intelligence (AI)
DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER Vancouver, BC, Canada, February 16th, 2022 -- InvestorsHub NewsWire Defence Therapeutics Inc...
Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9 Vancouver, BC, Canada, January 26th...
Vancouver, BC, Canada -- November 30th 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. (CSE: DTC; FSE: DTC; USOTC: DTCFF) ("Defence" or the...
DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER Vancouver, BC, Canada -- November 23, 2021 -- InvestorsHub NewsWire...
DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS Vancouver, BC, Canada, November 9th, 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. CSE:DTC, USOTC:DTCFF...
VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS Vancouver, BC, Canada, November...
DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER Vancouver, BC, Canada, October 13th...
DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA Vancouver, BC, Canada, October 6th, 2021 -- InvestorsHub NewsWire -- Defence...
DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER Vancouver, BC, Canada, September 29th, 2021 - InvestorsHub NewsWire -- Defence Therapeutics Inc...
DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS Vancouver, BC, Canada, September 20th, 2021 -- InvestorsHub NewsWire -- Defence...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.04 | 6.55737704918 | 0.61 | 0.7 | 0.6 | 48875 | 0.65084399 | CS |
| 4 | 0.13 | 25 | 0.52 | 0.76 | 0.49 | 31535 | 0.58919912 | CS |
| 12 | 0.05 | 8.33333333333 | 0.6 | 0.76 | 0.49 | 26260 | 0.57911451 | CS |
| 26 | -0.16 | -19.7530864198 | 0.81 | 0.96 | 0.48 | 30468 | 0.64633757 | CS |
| 52 | -1.77 | -73.1404958678 | 2.42 | 2.42 | 0.48 | 29916 | 1.02043265 | CS |
| 156 | -4.46 | -87.2798434442 | 5.11 | 5.3 | 0.48 | 19761 | 2.0358276 | CS |
| 260 | -1.1 | -62.8571428571 | 1.75 | 8.15 | 0.48 | 18706 | 2.51034094 | CS |
Man6677
3 years ago
newspopper
3 years ago
newspopper
3 years ago
newspopper
3 years ago
newspopper
3 years ago
GOLDBUFFALO
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
